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Abstract 
Cytotoxic T cells are of central importance in the immune system’s response to disease. They 
recognize defective cells by binding to peptides presented on the cell surface by MHC (major 
histocompatibility complex) class I molecules. Peptide binding to MHC molecules is the single 
most selective step in the antigen presentation pathway. On the quest for T cell epitopes, the 
prediction of peptide binding to MHC molecules has therefore attracted large attention. 
In the past, predictors of peptide-MHC interaction have in most cases been trained on binding 
affinity data. Recently an increasing amount of MHC presented peptides identified by mass 
spectrometry has been published containing information about peptide processing steps in the 
presentation pathway and the length distribution of naturally presented peptides. Here, we 
present NetMHCpan-4.0, a method trained on both binding affinity and eluted ligand data 
leveraging the information from both data types. Large-scale benchmarking of the method 
demonstrates an increased predictive performance compared to state-of-the-art when it comes 
to identification of naturally processed ligands, cancer neoantigens, and T cell epitopes.  
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 Introduction 
Cytotoxic T cells play a central role in the immune regulation of pathogenesis and malignancy.  
They perform the task of scrutinizing the surface of cells for the non-self peptides presented in 
complex with MHC (major histocompatibility complex) molecules. In cases such peptides are 
recognized, an immune response can be initiated potentially leading to killing of the infected 
(mal-functioning) cell. The most selective step in the pathway leading to this peptide 
presentation is the binding to MHC.  
 
Over the last decades, large efforts have been dedicated to the development of computational 
methods capable of accurately predicting this event. The accuracy of these methods has 
improved substantially over the last years, and most recent benchmark results demonstrate that 
more than 90% of naturally presented MHC ligands are identified at an impressive specificity of 
98%1. This gain in performance is achieved partly by the extended experimental binding data 
sets made available in the IEDB2, and partly by the development of novel machine-learning 
algorithms capable of capturing the information in the experimental binding data in a more 
effective manner. One such novel method is NNAlign-2.0, allowing the integration of peptides of 
variable length into the machine-learning framework 3. This novel training approach allows both 
the incorporation of a larger set of training data, but also and maybe more importantly enables 
the method to directly learn the length preference presented peptides for each MHC molecule 
from the experimental binding data 4. Even though most presented MHC class I ligands are of 
length 9 amino acids, the ability to incorporate length preferences directly into the model is 
critical as experimental data demonstrate that the length profiles of presented ligands can vary 
substantially between MHC molecules; prominent examples are the mouse H-2-Kb, with a 
preference for eight amino acids-long peptides 5 and HLA-A*01:01, where close to one third of 
MHC presented peptides have a length longer than nine amino acids 6.   
 
Some of the most well documented and applied of methods for predicting peptide binding to 
MHC class I include NetMHC 7,8, and NetMHCpan 4,9. These tools have over the last years 
gained increasing interest due to the recent focus on neoantigen identification within the field of 
personalized immunotherapy 10,11. However, as underlined in several studies including the 
recent Nature Biotechnology Editorial 12, “neoantigen discovery and validation remains a 
daunting problem”, mostly due to the relative high false positive rate of predicted epitopes.  
 
One potential cause for this relatively high rate of false positive epitope predictions is the fact 
that most methods are trained on binding affinity data, and as a consequence only model the 
single event of peptide-MHC binding. As stated above this binding to MHC is the most selective 
step in peptide antigen presentation. However, other factors including antigen processing 13 and 
the stability of the peptide:MHC complex 14 could influence the likelihood of a given peptide to 
be presented as an MHC ligand. Similarly, the length distribution of peptides available for 
binding to MHC molecules is impacted by other steps in the processing and presentation 
pathway, such as TAP transport and ERAP trimming, which are not reflected in binding data in 
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itself 6. Advances in mass spectrometry (MS) have allowed the field of MS peptidomics to move 
forward. In this context, recent studies 15,16 have suggested that training prediction methods on 
such data rather than binding affinity data could improve the ability to accurately identify MHC 
ligands. As such, MS peptidome data would contain the comprehensive signal of antigen 
processing and presentation rather than just MHC binding affinity. Moreover MS peptidome data 
generated by immunopeptidomic studies would contain precise information about the allele-
specific peptide length profile preferences not available in the MHC binding affinity data sets.  
 
Identification of MHC bound peptides by mass spectrometry thus holds great promise for the 
generation of large scale data sets characterizing the peptidome specific for individual MHC 
molecules 17, and potentially also for the identification of T cell epitopes 18.  It is however clear 
that, within the foreseeable future, the number of MHC molecules characterized by such MS 
studies will remain limited. In this context, large efforts have over the last decades been 
dedicated to experimentally characterize the peptide binding space of MHC molecules using 
semi high-throughput MHC-peptide binding affinity assays 19,20, enabling binding specificity 
characterization of a large set of MHC molecules from different species.  
 
The IEDB contains a comprehensive set of MHC binding and ligand data available in the public 
domain. While this data set contains binding affinity data characterizing more than 150 different 
MHC class I molecules (from human, non-human primates, mouse, and life-stock), at the onset 
of this study only 55 MHC class I molecules were characterized by MS peptidome data. This 
imbalance made us suggest a novel machine learning approach integrating information from 
both types of data (binding affinity and MS ligands) into a combined framework benefitting from 
information from the two worlds. The proposed framework is “pan-specific” as it can leverage 
information across MHC molecules, data types, and peptide lengths into one single model. We 
hence expect this approach to achieve superior predictive performance compared to models 
trained on the two data types individually, and also achieve an improved performance when it 
comes to predicting length profile preferences of different MHC molecules.  
 
While recent works have demonstrated the improved ability to identify MHC ligands using 
methods trained on MS peptidome data 15,16, limited data is available on their impact for the 
identification of T cell epitopes.  In this work, we focus on demonstrating the improved prediction 
performance not only on large sets of MS peptidome data but also on T cell epitope data 
independent from the data used to train the new predictor.  
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Results 
We trained the NetMHCpan method version 4.0 for the prediction of the interaction of peptides 
with MHC class I molecules integrating binding affinity and MS eluted ligand data. Combined 
training was achieved by adding a second output neuron to the NNAlign approach described 
previously 4. In this setup, the first output neuron returns a score of binding affinity, and the 
second output neuron a score of ligand elution. As described in the online methods section, the 
model parameters between the input and hidden layer of the artificial neural network are shared 
between the two input types. Thanks to this network architecture, we expect the model to be 
able to combine informative patterns found in the two data types, boosting performance for both 
output neurons. To demonstrate this, we compared the performance of the BA+EL method to 
the BA method, trained only on binding affinity data and the EL method trained only on eluted 
ligand data. Figure 1 shows the mean performance per MHC allele of the four methods on four 
different data sets given in in terms of AUC (for details see Supplementary Tables 1-3). From 
this analysis, it is clear that especially the BA+EL method with EL predictions performs much 
better on binding affinity data than the EL only method.  This observation strongly suggests that 
the EL only method, as a results of the small number of only 55 different MHC molecules 
included in the eluted ligand data set, has limited pan-specific potential compared to the BA+EL 
EL method trained on data from 169 MHC molecules included in the combined binding and MS 
eluted ligand data set.   
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Figure 1: Mean performance per MHC molecule measured in terms of AUC for the four methods; BA (trained on 
binding affinity data only), EL (trained on eluted ligand data only), BA+EL BA (the binding affinity prediction value of 
the model trained on the combined binding affinity and eluted ligand data), and BA+EL EL (the eluted ligand 
likelihood prediction value of the model trained on the combined binding affinity and eluted ligand data) The methods 
were evaluated on all binding affinity (all_BA) data and all eluted ligand (all_EL) data including negative peptides 
derived from source proteins, and on data sets restricted to alleles occurring in both binding affinity and eluted ligand 
data sets (shared_BA, and shared_EL).  
Peptide length preference of MHC molecules 
We next set out to investigate how well the different methods could capture the peptide length 
preferences of individual MHC molecules. For this, we predicted binding scores for a set of 
random natural peptides of lengths 8-15 amino acids and calculated the frequencies of peptides 
of different lengths in the top 2% of predictions. In figure 2a-c, we visualize examples of such 
peptide length preference profiles predicted by the BA, BA+EL BA, BA+EL EL, and EL only 
methods. The depicted MHC molecules are known to have preferences for different peptide 
lengths. All HLAs have a preference for 9mer peptides. However HLA-A*01:01 has an increased 
preference for 10-mers compared to average, HLA-A*02:01 has a strong preference for  9-mers 
only, and HLA-B*51:01 has an increased preference for  8-mers compared to average 4,6,17. 
Binding affinity predictors often overestimate the amount of binding 10-mer peptides due to their 
over-representation in the binding affinity data set 7,8, which is also visualized in figure 2. 
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Figure 2:  a-c) Predicted length preference of selected MHC molecules according to different models. Binding to 
selected HLA molecules was predicted for 80,000 8-15-mer peptides and the frequency of peptide lengths in the top 
2% predicted peptides calculated. d) Correlation of predicted and observed ligand length for different models. Binding 
to all HLA alleles present in both binding affinity and eluted ligand data sets was predicted using the four different 
prediction methods for 80,000 8-15-mer peptides. Subsequently the occurrence of different peptide lengths in the top 
2% predicted peptides for each molecule was calculated, and the correlation coefficient between these frequencies 
and the length frequencies in the eluted ligand data set calculated. 
 
Next, we extended the analysis to all MHC molecules included in the eluted ligand data set, 
calculating the correlation between observed and predicted length frequencies for each 
prediction method. This analysis (figure 2d) clearly confirms the results obtained from the 3 case 
examples, namely that the two methods BA+EL EL and EL only show significantly higher power 
for predicting the peptide length preference of individual MHC molecules compared to the two 
methods trained to predict binding affinity (BA, and BA+EL BA).    
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The predictions for the two eluted ligand likelihood models only show low performance for one 
molecule; HLA-B41:04. This molecule is however only characterized by 52 eluted ligands, 
whose length profile forms an unusual bimodal distribution with peaks at length 9 and 11 (data 
not shown).   
Leave-one-out experiments on eluted ligand data 
In the above experiment, the MHC molecules used for the peptide length preference evaluation 
were also included as training data of the EL prediction methods. This naturally leads to a bias 
in the performance evaluation. To address this, and to access the pan-specific potential of the 
BA+EL EL prediction method, we conducted a leave-one-out experiment. Here, a given MHC 
molecule was removed from the eluted ligand data set, and the BA+EL method retrained as 
described in material and methods. Next, both the predictive performance (estimated in terms of 
AUC for separating the known ligands from the artificial negatives) and the ability to predict the 
peptide length preference were evaluated. The result of the benchmark is shown in figure 3. 
This figure clearly confirms the pan-specific power of the BA+EL method. In terms of the 
predictive performance (figure 3a), the LOO methods display, as expected, a slight decrease in 
performance compared to a method trained and evaluated on all data (the all data method). 
When looking at the performance for predicting the peptide length profile (figure 3b), the LOO 
methods display a very high performance. Only in one case, the EL LOO method shows a 
substantial drop in performance for the left out MHC molecule. This case is H2-Kb, the only 
mouse molecule in the MS ligand data set with a strong preference for 8mer ligands. The 
BA+EL EL LOO method is able to predict the length profile of H2-Kb due to the H2-Kb affinity 
data present in the BA training data set. 
 
 
 
Figure 3: Eluted ligand leave-one-out experiments. a) Performance per MHC allele of a model trained on all data and 
a model where the eluted ligand data of a given allele was left out of the training process. b) Correlation of predicted 
and observed ligand length for a model trained on all data and the leave-one-out models. 
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The NetMHCpan-4.0 method 
Having demonstrated the increased predictive power of the BA+EL method when it comes to 
prediction of peptide binding affinity (the BA+EL BA model), likelihood of being an eluted ligand 
(BA+EL EL model), and the ability of capturing the MHC specific peptide length binding 
preferences (also the BA+EL EL model), we set out to construct the final NetMHCpan-4.0 
method. This method was trained as the BA+EL method, using 5 fold cross-validation as 
described in materials and methods. The method is accessible at 
www.cbs.dtu.dk/services/NetMHCpan-4.0. The functionality is identical to the earlier 
NetMHCpan implementations with the important additional functionality that two different output 
options (binding affinity and eluted ligand likelihood) are available. By default, the program 
returns eluted ligand likelihood scores. An example of the output of the method is shown in 
Supplementary figure 1.  
Validation on external data sets 
The performance of the updated NetMHCpan method was assessed on two independent 
external data sets; one consisting of 15,965 eluted ligands covering 27 HLA molecules, and 
another consisting of 1,251 validated CTL epitopes covering 80 HLA molecules reported in the 
IEDB. The validation data sets were constructed as described in online methods. The source 
protein sequence was identified for each ligand/epitope, and all overlapping 8-14 mer peptides 
except the ligand/epitope were annotated as negatives. All data points included in the binding 
affinity and eluted ligand training data sets were excluded from the validation data set. A Frank 
value was calculated for each positive-HLA pair as described in online methods as the ratio of 
the number of peptides with a prediction score higher than the positive peptide to the number of 
peptides contained within the source protein. In this manner, we can construct the sensitivity 
curves presented in figure 4. Two observations are striking from these results. First and 
foremost, the results clearly demonstrated the increased predictive power of integrating eluted 
ligand data into the training data of NetMHCpan. In the left panel (the analysis of the eluted 
ligand data), we can observe that the gain in sensitivity at a Frank threshold of 1% for the EL 
models (NetMHCpan-4.0 EL or EL only) compared to NetMHCpan-3.0 is 10% (95% versus 
85%), and 15% at a Frank threshold of 0.5% (90% versus 75%). These numbers mean that a 
ligand will have a prediction score within the top 0.5% of its source protein peptides in 90% of 
the cases using the EL models, compared to only 75% using NetMHCpan-3.0. The results 
shown in the left panel of figure 4 however also suggest that the two EL models achieve very 
similar predictive performance when it come to identification of eluted ligands. This is in strong 
contrast to the results obtained from the IEDB epitope data set (figure 4, right panel). Here, only 
the NetMHCpan-4.0 EL model demonstrates an improved predictive performance compared to 
NetMHCpan-3.0. The reasons for this inconsistency stem from the large overlap between the 
HLA molecules shared between the evaluation data sets and the training data. 20 of the 25 HLA 
molecules in the eluted ligand evaluation data are included in the eluted ligand training data, 
and this number only increases to 23 by adding in the binding affinity training data. This large 
overlap in MHC coverage between training and evaluation data makes the reduced pan-specific 
potential of the “EL (only)” model of limited importance.  In contrast to this, only 37 of the 80 
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HLA molecules in the IEDB T cell epitope data set are part of the eluted ligand training data, 
and this number is increased to 64 by including the binding affinity training data. So for this data, 
the performance of the “EL (only)” model is clearly compromised by its limited pan-specific 
power.  
 
 
Figure 4: Sensitivity of different models as a function of the Frank threshold on a) eluted ligands published by 
Pearson et al. 17 and b) T-cell epitope data downloaded from IEDB. 
To be or not to be a ligand 
We investigated what prediction threshold to use to best separate ligand from non-ligand 
peptides. Earlier work by others and us  suggests that different MHC molecules present 
peptides at different predicted binding affinity thresholds 4,21. Given this, it was interesting to 
investigate to what degree a similar observation could be made for the eluted ligand likelihood 
predictions produced by the NetMHCpan-4.0 method. To address the question, we compared 
the predicted ligand likelihood scores of all 15,965 ligands in the Pearson data set. The result of 
this analysis is displayed as box-plots in the left panel of Supplementary figure 2. This figure 
reveals that the likelihood prediction scores for known ligands come out very different for 
different HLA molecules. The large difference in prediction values between HLA molecules can 
to a high degree be linked to their absence from the eluted ligand training data. The molecules 
with lowest median eluted ligand likelihood scores in this figure are molecules absent from the 
eluted ligand training data set.  However, as demonstrated in figure 3 and 4, the fact that an 
HLA molecule has not been characterized with eluted ligand training data does not impair its 
predictability. Given this, a natural measure to correct for this great imbalance in prediction 
score is use percentile rank scores to reconcile and make prediction score comparable between 
different MHC molecules. The right panel of Supplementary figure 2 shows the results of such a 
transformation. Here, eluted ligand likelihood prediction values for each ligand in the Pearson 
data are transformed to percentile rank scores, and the score distribution is visualized as box 
plots for each HLA molecule. Given that percentile rank values fall in the range 0-100%, it is 
apparent that transforming the prediction values into such rank scores, allows for a direct score 
comparison between HLA molecules.  
 
In light of these results, we next investigated what percentile rank threshold to apply to optimally 
identify MHC ligands. We assess this by calculating sensitivity/specificity curves as a function of 
the percentile rank score threshold for a balanced set (max 100 ligands per HLA) of eluted 
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ligands and source protein negatives from the Pearson evaluation data set. The results are 
shown in figure 5 and confirm earlier findings that the vast majority (96.5%) of natural ligands 
are identified at a very high specificity (98.5) using a percentile rank threshold of 2%.  
 
 
Figure 5: Sensitivity and specificity performance curves for the NetMHCpan-4.0 eluted ligand likelihood predictions. 
Curves are estimated from a balanced set of eluted ligands from the 17 data set. The insert shows the complete 
sensitivity and specificity curves as a function of the percentile rank score. The main plot shows the curves in the 
high-scoring range for 0-5 percentile scores. Dotted vertical and horizontal lines are guides to the eye indicating 
sensitivity and specificity and the 2% rank score threshold. 
Identification of cancer neoantigens 
A research field where prediction of naturally processed and presented eluted ligand has 
attracted large recent attention is rational identification of cancer neoantigens. In contrast to 
tumor-associated self-antigens, cancer neoantigen are naturally presented ligands containing 
tumour-specific mutations. Such neoantigens are attracting large attention since these peptides 
are new to the immune system and not found in normal tissues, and hence are ideal potential 
cancer vaccine candidates or targets for adoptive T cell therapy. Depending on the mutational 
load, the number of potential tumour-specific neopeptides (peptides containing one or more 
missense mutations) can be in the order of many thousands 22. This large number of potential 
peptide candidates clearly underlines the need for tools to rationally downsize the peptide space 
in the search for cancer neoepitopes. A recent study by Bassani-Sternberg et al.18 
demonstrated how this downsizing could be effectively achieved by a prediction method trained 
on a large set of MS eluted ligands. Here, we repeated this benchmark analysis using 
NetMHCpan-4.0. The results are shown in figure 6 and confirm the finding by Bassani-
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Sternberg et al., that predictors trained on MS eluted ligand data information in most cases 
show very high predictive power for the identification of cancer neoantigens. Both the 
NetMHCpan-4.0 and Bassani-Sternberg methods identify the known neoantigen within the top 
25 peptides in 6 out out 10 cases. NetMHCpan-3.0 only achieves this in 2 out of 10 cases. The 
results also confirm the earlier findings presented here, that NetMHCpan-4.0 achieves improved 
performance compared to that of version 3.0, and that the ligands in all cases are predicted with 
very strong eluted ligand likelihood values (all percentile rank values are less than 1, and the 
majority are less than or equal to 0.02).  
 
 
Figure 6: Predictive performance evaluated in terms of rank of neo-antigens identified in four melanoma samples. A 
rank value of 1 corresponds to the ligand obtaining the highest score (lowest percentile rank) of all peptides from the 
given sample. Data and performance value for Bassani-Sternberg is from 18. NetMHCpan-4.0 and NetMHCpan-3.0 
are performance values obtained by assigning to each peptide in the given data set the lowest percentile rank score 
to each of the HLA-A and B molecules expressed by the given cell line. The values in parentheses for NetMHCpan-
4.0 are the predicted percentile rank values.  Lowest rank value for each ligand is highlighted in bold.  
Discussion 
In this work, we have demonstrated how a relatively simple pan-specific machine learning 
method based on the NNAlign framework can be constructed integrating information from 
binding affinity data with MS peptidome data. Benefitting from the larger set of peptide binding 
affinity data with very broad MHC coverage (more than 150 molecules), and the additional 
information contained within MS peptideome data (information about both antigen processing 
and presentation, and allele specific peptide length profile), we could demonstrate that the 
proposed method, NetMHCpan-4.0, achieved improved predictive performance not only when it 
comes to characterizing the binding specificity of a given MHC molecule, but also when it comes 
to predicting the peptide length profile. Due to the pan-specific potential of the method, the 
improved performance was extended beyond the relatively few MHC molecules characterized 
by MS binding data included in the training of the method. Given this, we thus conclude that the 
proposed framework is able to benefit from the best of the two data sets; MHC coverage from 
the binding affinity data, and antigen processing and presentation, and allele specific peptide 
length profile from the MS data.  
 
Sample Ligand NetMHCpan-4.0 NetMHCpan-3.0 Bassani-Sternberg et al.  #peptides 
Mel8 SPGPVKLEL 1 (0.0124) 12 2  1340 
Mel5 YIDERFERY 15 (0.0077) 33 3  25807 
Mel5 ETSKQVTRW 189 (0.1156) 464 13  25807 
Mel15 GRIAFFLKY 21 (0.0098) 224 3  24766 
Mel15 LPIQYEPVL 10 (0.0071) 24 7  24766 
Mel15 KLKLPIIMK 6 (0.0061) 34 21  24766 
Mel15 GRTGAGKSFL 1226 (0.6909) 2186 243  24766 
Mel15 KLILWRGLK 457 (0.2364) 112 527  24766 
Mel15 ASWVVPIDIK 1629 (0.9723) 1278 3978  24766 
12T DANSFLQSV 19 (0.0205) 944 38  15750 
	
Our benchmarks confirmed earlier findings that prediction values for known ligands vary 
substantially between MHC molecules 4, and that only by the use of percentile rank scores can 
predictions between different MHC molecules be readily compared. 
 
The improved peptide-MHC tool is made publicly available at 
www.cbs.dtu.dk/services/NetMHCpan-4.0. The tool was benchmarked on two large independent 
data sets; one consisting of ~16,000 MS identified MHC restricted ligands 17 and one consisting 
of more than 1,250 validated T cell epitopes described in the IEDB. For both data sets, the 
updated version 4.0 of NetMHCpan significantly outperformed the earlier method (3.0). In 
particular, the benchmark on T cell epitope data - to the best of our knowledge - demonstrated 
for the first time how integration of MS peptidome data into a prediction method of MHC peptide 
presentation, can lead to improved predictive performance for T cell epitope discovery. The 
improved performance on this data set was only observed for the method trained on the 
combined data, and was not observed for the method trained on MS peptidome data alone. This 
observation underlines the large benefit of merging the two data sets, gaining pan-specific 
potential from the large MHC coverage of the binding affinity data.    
 
The machine-learning framework proposed here is not limited to the integration of MHC class I 
peptide binding affinity and MS peptidome data. The approach can readily be extended to 
integrate other types of relevant data including MHC binding stability 23, and epitope data. Also, 
the approach can in its current form be directly applied to the MHC class II system. The only 
critical limitation for such data integrations is the criteria that each data point must be associated 
with a specific MHC element. This information is not always readily available, but can in most 
cases be inferred by unsupervised clustering of the available data (using GibbsCluster 24, 
position weight matrix mixture models 25, or similar approaches), and association of each cluster 
to an MHC molecule of the given host.  
 
In conclusion, we have here described a new framework for training of prediction methods for 
MHC peptide presentation prediction integrating information from two data sources (MS eluted 
ligand and peptide binding affinity). The framework was used to develop an updated version of 
NetMHCpan (version 4.0, available at www.cbs.dtu.dk/services/NetMHCpan-4.0) with improved 
predictive performance for identification of validated eluted ligands, cancer neoantigens and T 
cell epitopes. 
 
 
  
 Online Methods 
Data sets 
 
Data on all class I MHC ligand elution assays available in IEDB database (www.iedb.org) were 
collected including the ligand sequence, details of the source protein, position of the ligand in 
the source protein and the restricting allele of the ligand. There were 160,527 distinct assays in 
total and the length of the ligands ranged from 4-37. All lengths with a count of ligands at least 
0.5% of total ligands were selected for further analysis which included lengths 8-15 and 
comprised of 99% of the assay entries. 
 
The restricting MHC molecule of the ligands were analyzed and entries with alleles listed 
unambiguously were selected. For example, some entries where the HLA alleles are listed as 
just the gene name and alleles from chicken, horse, cow and mouse for which we did not have 
binding prediction algorithms were excluded. Representative alleles were assigned for entries 
where only supertypes were listed (e.g. HLA-A*26:01 for HLA-A26). Thus there were 127 class I 
molecules from human and mouse in the selected data set. Redundant entries with same ligand 
sequence and MHC molecule were removed and MHC molecules with at least 50 ligand entries 
were selected. This included 55 class I molecules and the number of available ligands per 
molecule varied widely from 50 to 9500.  
 
We hypothesized that some of the ligands could be artifacts of the elution assays and therefore 
their source proteins could be false positive as antigens. A protocol was designed to identify 
such false positive antigens and exclude them from the final data selected. The protocol 
identified proteins that had significantly lesser number of predicted binders among ligands than 
expected of random peptides using binomial probability distribution. Five sets of random 
peptides were generated from the ligand sequences by shuffling the amino acid residues within 
the ligands. Binding affinity was then predicted for the original ligands and random peptide sets 
for their corresponding alleles. The median of the predicted percentile ranks of the five random 
sets was estimated and assigned as the binding affinity of the random peptides. Based on a 
predicted binding affinity cutoff of percentile rank 1.0, the number of predicted binders among 
the original ligands and the random peptide sets were estimated. Five proteins were thus 
identified as false positives and ligand entries from these proteins were excluded from the data 
set. 
 
The final data set had 85,217 entries in total with ligand length ranging from 8 to 15. The ligands 
originated from 14,797 source antigens and were restricted by 55 unique HLA molecules.  
 
Random artificial negatives were generated for each MHC molecule covered by eluted ligand 
data by sampling randomly 10*N peptides of each length 8-15 amino acids from the antigen 
source protein sequences, where N is the number of 9mer ligands for the given MHC molecule. 
Neural network training 
The NNAlign training approach with insertions and deletions 4 was extended by adding a 
second output neuron as shown in figure 7. This was done to allow combined training on 
binding affinity and MS eluted ligand data. Binding affinity values are measured as IC50 values 
in nM (aff) and can be rescaled to the interval [0,1] by applying 1-log(aff)/log(50,000), 
representing continuous target values 26. For eluted ligands the strength of the interaction 
between peptide and MHC molecules is unknown, therefore a target value of 1 is assigned to 
binders and 0 to artificial negative peptides (see above).  
 
 
Figure 7: Visualization of the neural networks with two output neurons used for combined 
training on binding affinity and eluted ligand data. 
 
In this network architecture weights between the input and hidden layer are shared between the 
two input types (binding affinity/ligand), and weights connecting the hidden and output layer are 
specific for each input type. During neural network an example is randomly selected from either 
data set and submitted to forward- and backpropagation according to the NNAlign algorithm 4. In 
this setting, we define one training epoch as the average number of iterations needed to 
process each data point in the smaller data once.  
 
A neural network ensemble was trained as described by Andreatta et al. 4 using 5-fold nested 
cross-validation. Networks with 60 and 70 hidden neurons were trained leading to an ensemble 
of 40 networks in total. 
 
The inputs to the neural networks consisted of the peptide and the MHC molecule in terms of a 
pseudo sequence 9. All peptides were represented as 9-mer binding cores by the use of 
insertions and deletions as described by Andreatta et al.  4 and are were represented using 
BLOSUM encoding 26. As in the earlier work by Andreatta et al., additional features for the 
encoding of peptides included: the length of the deletion/insertion; the length of peptide flanking 
regions, which are larger than zero in the case of a predicted extension of the peptide outside 
either terminus of the binding groove; and the length L of the peptide, encoded with four input 
neurons corresponding to the four cases L<=8, L=9, L=10, L>=11. 
Performance 
In order to benchmark the combined training method described above (referred to as BA+EL), 
additional methods with only one output but otherwise identical setup were trained on binding 
affinity data only (BA data) and eluted ligand data only (EL method). 
AUC values were calculated for each MHC alleles separately and subsequently binomial tests 
were performed to compare the different models. 
Length preference of MHC molecules 
For all MHC molecules shared between the binding affinity and eluted ligand data sets, we 
generated predictions for 80,000 random natural peptides of lengths 8-15 amino acids (10,000 
of each length). From the top 2% predictions, the frequency of each peptide length was 
estimated. Subsequently Pearson's correlation coefficient was calculated between the 
frequencies observed in the eluted ligand data set and the frequencies predicted by 4 models 
(BA only, EL only, binding affinity of BA+EL, and eluted ligand predictions of BA+EL) 
Leave-one-out validation 
Leave-one-out experiments were performed for all MHC molecules present in the eluted ligand 
data set. For this, a given MHC molecule was removed from the eluted ligand data set, then the 
BA+EL method was trained in five fold-cross validation as described above, omitting multiple 
random initializations, resulting in an ensemble of 10 networks. Performance of the leave-one-
out models is compared to an ensemble of neural networks of the same size trained on the 
complete data set. Further predictions are made for 80,000 peptides of lengths 8-15 amino 
acids derived from natural proteins to evaluate a model’s ability to predict the length preference 
of an MHC allele that was not part of the eluted ligand training data. 
The final NetMHCpan-4.0 method implementation 
The final neural network ensemble of the NetMHCpan-4.0 method is trained on binding affinity 
and eluted ligand data as described above using 5-fold cross-validation. Networks with 56 and 
66 hidden neurons (in accordance with earlier NetMHCpan implementations) were trained using 
10 distinct random initial configurations, leading to an ensemble of 100 networks in total. 
 
Percentile rank scores was estimated from predicted EL and BA binding values from a set of 
125,000 8-12mer random natural peptides (25,000 of each length) 
Validation on external data sets 
 
A dataset of eluted ligands was obtained from Pearson et al. 17. Also, a set of positive CD8 
epitopes was downloaded from the IEDB. The epitope set was identified using the following 
search criteria “T cell assays: IFNg", "positive assays only", "MHC restriction Type: Class I". 
Only entries with fully typed HLA restriction, peptides length in the range 8-14 amino acids, and 
with annotated source protein sequence were included. Positive entries with a predicted rank 
score greater than 10% using NetMHCpan-3.0 were excluded to filter out likely noise 6. For both 
the T-cell epitope and eluted ligand data sets, negative peptides were obtained by extracting all 
8-14 mer peptides from the source proteins of the eluted ligands and subsequently excluding 
peptides-MHC combination found with an exact match in the training data (both binding affinity 
and eluted ligand data sets). The final eluted data set contained 15,965 positive ligands 
restricted to 27 different HLA molecules, and the IEDB T cell epitope data set 1,251 positive T 
cell epitopes restricted to 80 HLA molecules.  
 
A Frank value was calculated for each positive-HLA pair as the ratio between the number of 
peptides with a prediction score higher than the positive peptide and the number of peptides 
contained within the source protein. The Frank value is hence 0 if the positive peptide has the 
highest prediction value of all peptides within the source protein, and a value of 0.5 in cases 
where an equal amount of peptides has a higher and lower prediction value compared to the 
positive peptide.  
 
  
 Figure legends 
Figure 1: Mean performance per MHC molecule measured in terms of AUC for the four 
methods; BA (trained on binding affinity data only), EL (trained on eluted ligand data only), 
BA+EL BA (the binding affinity prediction value of the model trained on the combined binding 
affinity and eluted ligand data), and BA+EL EL (the eluted ligand likelihood prediction value of 
the model trained on the combined binding affinity and eluted ligand data) The methods were 
evaluated on all binding affinity (all_BA) data and all eluted ligand (all_EL) data including 
negative peptides derived from source proteins, and on data sets restricted to alleles occurring 
in both binding affinity and eluted ligand data sets (shared_BA, and shared_EL).  
 
Figure 2:  a-c) Predicted length preference of selected MHC molecules according to different 
models. Binding to selected HLA molecules was predicted for 80,000 8-15-mer peptides and the 
frequency of peptide lengths in the top 2% predicted peptides calculated. d) Correlation of 
predicted and observed ligand length for different models. Binding to all HLA alleles present in 
both binding affinity and eluted ligand data sets was predicted using the four different prediction 
methods for 80,000 8-15-mer peptides. Subsequently the occurrence of different peptide 
lengths in the top 2% predicted peptides for each molecule was calculated, and the correlation 
coefficient between these frequencies and the length frequencies in the eluted ligand data set 
calculated. 
 
Figure 3: Eluted ligand leave-one-out experiments. a) Performance per MHC allele of a model 
trained on all data and a model where the eluted ligand data of a given allele was left out of the 
training process. b) Correlation of predicted and observed ligand length for a model trained on 
all data and the leave-one-out models. 
 
Figure 4: Sensitivity of different models as a function of the Frank threshold on a) eluted ligands 
published by Pearson et al. 17 and b) T-cell epitope data downloaded from IEDB. 
 
Figure 5: Sensitivity and specificity performance curves for the NetMHCpan-4.0 eluted ligand 
likelihood predictions. Curves are estimated from a balanced set of eluted ligands from the 17 
data set. The insert shows the complete sensitivity and specificity curves as a function of the 
percentile rank score. The main plot shows the curves in the high-scoring range for 0-5 
percentile scores. Dotted vertical and horizontal lines are guides to the eye indicating sensitivity 
and specificity and the 2% rank score threshold. 
 
Figure 6: Predictive performance evaluated in terms of rank of neo-antigens identified in four 
melanoma samples. A rank value of 1 corresponds to the ligand obtaining the highest score 
(lowest percentile rank) of all peptides from the given sample. Data and performance value for 
Bassani-Sternberg is from 18. NetMHCpan-4.0 and NetMHCpan-3.0 are performance values 
obtained by assigning to each peptide in the given data set the lowest percentile rank score to 
each of the HLA-A and B molecules expressed by the given cell line. The values in parentheses 
for NetMHCpan-4.0 are the predicted percentile rank values.  Lowest rank value for each ligand 
is highlighted in bold.  
 
  
Supplementary Figures 
 
 
Supplementary Figure 1: Output example from NetMHCpan-4.0. The protein sequence for ENSP00000363746 was 
screened for potential HLA-B*44:03 binders of length 8-12 using the eluled ligand prediction mode of NetMHCpan-
4.0. Only strong predictions (SB) are shown. For each peptide the binding core is reported (the peptide sequence 
predicted to be “seen” by the MHC molecule after accommodating indels), the Icore (the biological fragment predicted 
to form complex with the MHC including indels), the location and length of gaps, Gp/Gl (deletions) and insertions, 
Ip/Il, as well as the prediction score and predicted rank value. The two entries highlighted in red corresponds to eluted 
ligands contained within the Pearson data set 17. 
 
 
 
Supplementary Figure 2: Motivation for using percentile rank score predictions. Box-plot representation of prediction 
values for the ligands in the Pearson data set. Left panel: Eluted ligand likelihood prediction scores. Right panel: 
Percentile rank values.  
 
 
  
# NetMHCpan version 4.0 
 
# Input is in FSA format 
 
# Peptide length 8,9,10,11,12 
 
# Make Eluted ligand likelihood predictions 
 
HLA-B44:03: Distance to training data  0.000 (using nearest neighbor HLA-B44:03) 
 
# Rank Threshold for Strong binding peptides   0.500 
# Rank Threshold for Weak binding peptides   2.000 
----------------------------------------------------------------------------------------------------- 
Pos         HLA      Peptide      Core Of Gp Gl Ip Il        Icore        Identity Score %Rank BLevel  
----------------------------------------------------------------------------------------------------- 
534 HLA-B*44:03    KEQIERLGY KEQIERLGY  0  0  0  0  0    KEQIERLGY ENSP00000363746 0.906  0.06  <= SB       
498 HLA-B*44:03    QEWEVKALL QEWEVKALL  0  0  0  0  0    QEWEVKALL ENSP00000363746 0.835  0.10  <= SB      
236 HLA-B*44:03    MEAVRDIRF MEAVRDIRF  0  0  0  0  0    MEAVRDIRF ENSP00000363746 0.829  0.10  <= SB      
247 HLA-B*44:03 SEALLAVAQNRW SEALAQNRW  0  4  3  0  0 SEALLAVAQNRW ENSP00000363746 0.779  0.13  <= SB       
294 HLA-B*44:03    SETGFLTYL SETGFLTYL  0  0  0  0  0    SETGFLTYL ENSP00000363746 0.741  0.15  <= SB      
294 HLA-B*44:03     SETGFLTY SET-GFLTY  0  0  0  3  1     SETGFLTY ENSP00000363746 0.651  0.21  <= SB      
522 HLA-B*44:03     AEVDVISL AEVDVI-SL  0  0  0  6  1     AEVDVISL ENSP00000363746 0.625  0.24  <= SB      
533 HLA-B*44:03   KKEQIERLGY KEQIERLGY  0  1  1  0  0   KKEQIERLGY ENSP00000363746 0.520  0.33  <= SB      
 51 HLA-B*44:03 RELRPQRPKNAY RELRPQRAY  0  7  3  0  0 RELRPQRPKNAY ENSP00000363746 0.415  0.43  <= SB 
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